New York State Common Retirement Fund Acquires 25,164 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

New York State Common Retirement Fund boosted its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 14.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 204,482 shares of the biotechnology company’s stock after purchasing an additional 25,164 shares during the period. New York State Common Retirement Fund owned approximately 0.34% of Ascendis Pharma A/S worth $28,151,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Groupama Asset Managment purchased a new position in shares of Ascendis Pharma A/S in the third quarter valued at about $60,000. Janus Henderson Group PLC increased its position in shares of Ascendis Pharma A/S by 6.8% in the third quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after acquiring an additional 267,881 shares during the period. Westfield Capital Management Co. LP increased its position in shares of Ascendis Pharma A/S by 3.4% in the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock valued at $766,523,000 after acquiring an additional 170,942 shares during the period. Massachusetts Financial Services Co. MA increased its position in shares of Ascendis Pharma A/S by 9.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock valued at $278,760,000 after acquiring an additional 155,971 shares during the period. Finally, Frazier Life Sciences Management L.P. purchased a new position in shares of Ascendis Pharma A/S in the third quarter valued at about $19,908,000.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on ASND shares. The Goldman Sachs Group boosted their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Cantor Fitzgerald restated an “overweight” rating and issued a $170.00 price objective on shares of Ascendis Pharma A/S in a research report on Tuesday, February 11th. TD Cowen reduced their price target on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Finally, Wedbush reiterated an “outperform” rating and set a $181.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $197.36.

Ascendis Pharma A/S Stock Performance

Shares of ASND opened at $154.58 on Friday. The stock has a market cap of $9.38 billion, a PE ratio of -21.77 and a beta of 0.64. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $161.00. The firm’s 50-day simple moving average is $134.09 and its two-hundred day simple moving average is $132.88.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.64. Equities research analysts predict that Ascendis Pharma A/S will post -4.36 EPS for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.